Published • loading... • Updated
Boehringer Ingelheim strengthens obesity pipeline as potential first-in-class triple receptor agonist BI 3034701 enters Phase II development
Summary by Globe Newswire
12 Articles
12 Articles
The Toronto Star+11 Reposted by 11 other sources
Boehringer Ingelheim strengthens obesity pipeline as potential first-in-class triple receptor agonist BI 3034701 enters Phase II development
Boehringer Ingelheim announces the start of a Phase II clinical trial evaluating the efficacy and safety of its novel triple receptor agonist, BI 3034701, in people living with obesity and overweight.1BI 3034701 is a potential first-in-class GLP-1/GIP/NYP2 receptor agonist designed…
·Toronto, Canada
Read Full ArticleCoverage Details
Total News Sources12
Leaning Left6Leaning Right1Center3Last UpdatedBias Distribution60% Left
Bias Distribution
- 60% of the sources lean Left
60% Left
L 60%
C 30%
Factuality
To view factuality data please Upgrade to Premium
